The challenge of HTLV-1 therapeutics: lessons from anti-protease approaches
Sanaz Ahmadi Ghezeldasht, Raheleh Miri, Seyed Khosrow Shamsian, Arman Mosavat, Seyed Abdolrahim Rezaee · 2026
Read The challenge of HTLV-1 therapeutics: lessons from anti-protease approaches by Sanaz Ahmadi Ghezeldasht, Raheleh Miri, Seyed Khosrow Shamsian, Arman Mosavat, Seyed Abdolrahim Rezaee (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13251506.txt.
Description
Sanaz Ahmadi Ghezeldasht and colleagues review the hunt for drugs against HTLV-1, a leukemia-causing retrovirus, in 2026. Between five and twenty million people carry the virus worldwide, yet no direct antiviral therapy exists for it. The review centers on the viral protease, a scissor-like enzyme the virus needs to mature and become infectious.
Borrowing HIV protease blockers has largely failed, and the review explains why. The HTLV-1 enzyme grips its targets in a narrower, differently shaped pocket than its HIV cousin, so drugs fitted to one do not fit the other. The authors assess design strategies built around the enzyme's own structure, including computer screening of candidate molecules and combination chemistry. They argue that progress needs chemical starting points drawn for this protease alone. The piece closes with research directions meant to speed the first effective drug.
Catalog record
| CREATOR | Sanaz Ahmadi Ghezeldasht, Raheleh Miri, Seyed Khosrow Shamsian, Arman Mosavat, Seyed Abdolrahim Rezaee |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |